Fate Therapeutics, Inc.
FATE
$0.9205
-$0.0458-4.74%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 13.63M | 13.45M | 12.32M | 6.48M | 63.53M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 13.63M | 13.45M | 12.32M | 6.48M | 63.53M |
| Cost of Revenue | 118.53M | 117.80M | 117.42M | 123.70M | 157.19M |
| Gross Profit | -104.90M | -104.35M | -105.11M | -117.22M | -93.65M |
| SG&A Expenses | 90.64M | 92.25M | 90.40M | 95.77M | 96.86M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 209.17M | 210.05M | 207.82M | 219.47M | 254.04M |
| Operating Income | -195.54M | -196.60M | -195.51M | -212.99M | -190.51M |
| Income Before Tax | -186.26M | -178.23M | -175.72M | -190.05M | -160.93M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -186.26 | -178.23 | -175.72 | -190.05 | -160.93 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -186.26M | -178.23M | -175.72M | -190.05M | -160.93M |
| EBIT | -195.54M | -196.60M | -195.51M | -212.99M | -190.51M |
| EBITDA | -176.58M | -177.57M | -176.34M | -194.08M | -172.23M |
| EPS Basic | -1.65 | -1.65 | -1.71 | -1.92 | -1.63 |
| Normalized Basic EPS | -0.95 | -1.07 | -1.10 | -1.26 | -1.08 |
| EPS Diluted | -1.65 | -1.65 | -1.71 | -1.92 | -1.63 |
| Normalized Diluted EPS | -0.95 | -1.07 | -1.10 | -1.26 | -1.08 |
| Average Basic Shares Outstanding | 454.14M | 434.96M | 415.75M | 396.69M | 393.64M |
| Average Diluted Shares Outstanding | 454.14M | 434.96M | 415.75M | 396.69M | 393.64M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
